GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BerGenBio ASA (OTCPK:BRRGF) » Definitions » Investments And Advances

BerGenBio ASA (BerGenBio ASA) Investments And Advances : $0.00 Mil (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is BerGenBio ASA Investments And Advances?

BerGenBio ASA's Investments And Advances for the quarter that ended in Dec. 2023 was $0.00 Mil.


BerGenBio ASA Investments And Advances Historical Data

The historical data trend for BerGenBio ASA's Investments And Advances can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BerGenBio ASA Investments And Advances Chart

BerGenBio ASA Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Investments And Advances
Get a 7-Day Free Trial Premium Member Only - - - - -

BerGenBio ASA Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Investments And Advances Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

BerGenBio ASA Investments And Advances Calculation

Investments And Advances includes all the non-current investments in affiliates, real estate, securities, etc.


BerGenBio ASA (BerGenBio ASA) Business Description

Traded in Other Exchanges
Address
Mollendalsbakken 9, Bergen, NOR, 5009
BerGenBio ASA is a clinical stage oncology biotech company, which is engaged in developing therapeutics against novel drug targets that drive aggressive cancers. Its drug candidate bemcentinib (BGB324) is d is curently being developed in STK11 mutated NSCLC and severe respiratory infections including COVID-19. .

BerGenBio ASA (BerGenBio ASA) Headlines